🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →
Business news, market intelligence, and global industry analysis.
The Latest

Natco Pharma faces legal setback for Imbruvica generic in US

bySrinath
August 21, 2021
Total
0
Shares
0
0
0

Natco Pharma Limited said that a US District Court has given a decision in favor of Pharmacyclics, a subsidiary of AbbVie, the brand owner of Imbruvica (ibrutinib) in a PIV litigation that involved the cancer drug.

The Indian pharma company said that it will review the judgment and assess all options for appealing the judgment, alongside Alvogen Pine Brook, its marketing partner in the US for the product.

Natco Pharma said that it has a strong case and will continue to vigorously defend it.

Natco Pharma faces legal setback for Imbruvica generic in US
Natco Pharma faces legal setback for Imbruvica generic in US. Image courtesy of 3D Animation Production Company from Pixabay.

In 2018, the Hyderabad-based firm and Alvogen Pine Brook had filed an abbreviated new drug application (ANDA) with PIV certification for the generic equivalent of Imbruvica.

Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Bayer, Orion secures Darolutamide FDA approval for prostate cancer

Darolutamide FDA approval : German pharma giant Bayer and Finnish pharma company Orion have secured approval from the US Food and Drug Administration (FDA) for their non-steroidal androgen receptor inhibitor (ARi) Nubeqa (darolutamide) for the treatment of men having non-metastatic castration-resistant prostate cancer (nmCRPC). The FDA approval of darolutamide was driven on the findings of […]

The post Bayer, Orion secures Darolutamide FDA approval for prostate cancer appeared first on PharmaNewsDaily.com.

bypharmanewsdaily